Warning Letter — Meta Labs Pharmaceuticals, LLC
The FDA issued a warning letter to Meta Labs Pharmaceuticals, LLC following an evaluation under the Human Foods Program. The letter outlines regulatory violations regarding the company's products and marketing practices.
Meta Labs Pharmaceuticals, LLC and its quality, regulatory, and marketing personnel responsible for food and dietary supplement compliance.
This action indicates that the FDA is actively monitoring labeling and manufacturing claims under the Human Foods Program. While the specific nature of the violations is not detailed in the source excerpt, such letters typically signify concerns regarding product safety, unapproved drug claims, or failure to meet current good manufacturing practices. Regulatory teams should interpret this as a signal of continued enforcement rigor regarding product classification and safety standards.
Review all product labeling and marketing materials to ensure no unauthorized drug claims are being made for food products. Conduct a gap analysis of current manufacturing documentation against federal food safety and labeling requirements. Ensure that legal and regulatory teams oversee descriptions of intended use to avoid misclassification.
FDA Warning Letter issued to: Meta Labs Pharmaceuticals, LLC. 05/15/2026 — Human Foods Program. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/meta-labs-pharmaceuticals-llc-725130-05152026
Open in openFDA / FDA.gov